<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19709" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Collagen Vascular Disease Associated With Interstitial Lung</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lange</surname>
            <given-names>Steven M.</given-names>
          </name>
          <aff>Thomas Jefferson University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sankari</surname>
            <given-names>Abdulghani</given-names>
          </name>
          <aff>Wayne State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parekh</surname>
            <given-names>Maansi</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Steven Lange declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdulghani Sankari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maansi Parekh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19709.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Collagen vascular disease-associated interstitial lung disease (CVD-ILD) consists of several immunologically mediated diseases with characteristic pulmonary features. Diagnosis and management require an understanding of the combination of radiologic, histologic, physical, and functional findings. To avoid the high morbidity and mortality associated with CVD-ILD, an appropriate and comprehensive evaluation must be undertaken. This activity reviews the assessment and treatment of CVD-ILD and highlights the role of the interprofessional team in the care of patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the collagen vascular diseases and their associated interstitial lung diseases.</p></list-item><list-item><p>Differentiate the radiologic and pathological features of collagen vascular disease-associated interstitial lung disease.</p></list-item><list-item><p>Assess the importance of the evaluation of collagen vascular disease-associated interstitial lung disease and its role in management and prognosis.</p></list-item><list-item><p>Assess the importance of collaboration among the interprofessional team to improve outcomes for patients with collagen vascular disease-associated interstitial lung disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19709&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19709">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19709.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Interstitial lung disease (ILD) refers to&#x000a0;different manifestations of&#x000a0;pulmonary disorders due&#x000a0;to inflammation and/or fibrosis of the pulmonary parenchyma.&#x000a0;Collagen vascular disease is a common type of ILD etiology and encompasses a diverse group of immunologically mediated entities that share overlapping clinical and histopathologic features as well as manifest in characteristic patterns of ILD.<xref ref-type="bibr" rid="article-19709.r1">[1]</xref></p>
        <p>The collagen vascular diseases which commonly affect the pulmonary system include rheumatoid arthritis (RA), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), polymyositis (PM), dermatomyositis (DM), mixed connective tissue disease (MCTD), and Sjogren&#x02019;s syndrome (SS). The degree of lung involvement and spectrum of thoracic findings vary among the disorders, may be seen with clinically early or late disease, and&#x000a0;portends certain patient outcomes. Identification of pulmonary involvement has important therapeutic and prognostic implications.</p>
        <p>Collagen vascular disease may be associated with usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), diffuse alveolar damage (DAD), and lymphocytic interstitial pneumonia (LIP).<xref ref-type="bibr" rid="article-19709.r2">[2]</xref></p>
        <p>This article will review the etiology, epidemiology, pathogenesis, history and examination, evaluation, management, and prognosis of ILD&#x000a0;related to collagen vascular disease.</p>
      </sec>
      <sec id="article-19709.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Collagen vascular diseases are immunologically mediated diseases that may be idiopathic or influenced by genetic and environmental factors, such as medications, smoking, and sex hormones. The causes of connective diseases are mostly unknown, though the role of autoimmunity is well-established.<xref ref-type="bibr" rid="article-19709.r3">[3]</xref>&#x000a0;</p>
        <p>Rheumatoid arthritis is theorized to be instigated by an infectious agent with tissue damage mediated by tumor necrosis factor. Various cytokines have been identified as contributing to the inflammatory response. Systemic lupus erythematosus is thought to be caused by an interaction between gene susceptibility and environmental agents and inflammation mediated by the deposition of auto-antibodies in specific tissues. Various viruses, such as Ebstein-Barr,&#x000a0;<italic toggle="yes">Mycoplasma,</italic>&#x000a0;and <italic toggle="yes">Borrelia</italic>&#x000a0;bacterial species, have also been implicated as causes of systemic lupus erythematosus. Vascular injury is believed to be the initial pathologic event in scleroderma, while similar mechanisms of inflammation are involved in Sjogren's syndrome, polymyositis, and dermatomyositis.&#x000a0;</p>
        <p>For the undifferentiated form of connective tissue disease-related ILD, a new classification was proposed by the European Respiratory Society/American Thoracic Society Task Force called "Interstitial pneumonia with autoimmune features (IPAF)."<xref ref-type="bibr" rid="article-19709.r4">[4]</xref>&#x000a0;The&#x000a0;criteria for IPAF consist of the following:</p>
        <p>1. Presence of interstitial pneumonia by lung biopsy or HRCT and exclusion of alternative etiologies and2. Lack the presence of a defined&#x000a0;connective vascular disease and3. At least one feature from at least two of the following:</p>
        <list list-type="order">
          <list-item>
            <p>Clinical: Digital manifestation (ulcer, edema, etc.),&#x000a0;Raynaud phenomenon, or&#x000a0;polyarticular morning joint stiffness</p>
          </list-item>
          <list-item>
            <p>Serologic: ANA&#x02009;&#x02265;&#x02009;1:320 titer,&#x000a0;Rheumatoid factor&#x02009;&#x02265;2&#x02009;&#x000d7;&#x02009;upper limit,&#x000a0;Anti-CCP,&#x000a0;Anti-dsDNA, Anti-Ro (SS-A),&#x000a0;Anti-La (SS-B), Anti-ribonucleoprotein,&#x000a0;Scl-70,&#x000a0;Anti&#x02013;PM-Scl, or&#x000a0;Anti&#x02013;MDA-5.</p>
          </list-item>
          <list-item>
            <p>Morphologic: Radiologic (nonspecific interstitial pneumonia (NSIP) with or without organizing pneumonia or lymphoid interstitial pneumonia), histologic (NSIP with or without organizing pneumonia or lymphoid interstitial pneumonia), or unexplained pleural or pericardial effusion, or&#x000a0;pulmonary vasculopathy&#x000a0;suggested by PFT (i.e., unexplained decrease in Dl).<xref ref-type="bibr" rid="article-19709.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19709.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Approximately 30 % of patients with newly diagnosed ILD have underlying collagen vascular disease,<xref ref-type="bibr" rid="article-19709.r1">[1]</xref> although the exact frequency of&#x000a0;collagen vascular disease-associated&#x000a0;ILD is unknown.<xref ref-type="bibr" rid="article-19709.r6">[6]</xref>&#x000a0;Up to 90% of patients with&#x000a0;collagen vascular disease will have pulmonary involvement.&#x000a0;ILD prevalence on high-resolution computed tomography (HRCT) is 70%-90% in systemic sclerosis, 4%-68% in rheumatoid arthritis, 20%-85% in mixed connective tissue disease, 10%-30% in Sjogren's syndrome, and up to 30% in systemic lupus erythematosus.<xref ref-type="bibr" rid="article-19709.r7">[7]</xref>&#x000a0;Due to this high prevalence of CTD-ILD, most guidelines recommend excluding connective tissue disease in newly diagnosed ILD.<xref ref-type="bibr" rid="article-19709.r8">[8]</xref></p>
        <p>Rheumatoid arthritis affects up to two percent of the population, more commonly women, although rheumatoid arthritis-related&#x000a0;interstitial lung disease is more common in middle-aged men. The highest incidence occurs between the ages of 25 and 50 years. Extra-articular involvement is seen in up to half of patients with rheumatoid arthritis, with pulmonary disease as the second most common cause of death.<xref ref-type="bibr" rid="article-19709.r9">[9]</xref>&#x000a0;Clinically significant ILD in the form of&#x000a0;usual interstitial pneumonia (UIP) (most common), NSIP, or&#x000a0;cryptogenic organizing pneumonia is seen in approximately five percent of patients.<xref ref-type="bibr" rid="article-19709.r10">[10]</xref>&#x000a0;Acute interstitial pneumonia is a rare entity with a rapidly fatal course.<xref ref-type="bibr" rid="article-19709.r11">[11]</xref></p>
        <p>Progressive systemic sclerosis (SSc), or scleroderma, is a multisystem disease occurring predominantly in women. The highest incidence occurs between the ages of 45 and 64 years.<xref ref-type="bibr" rid="article-19709.r12">[12]</xref>&#x000a0;Patterns of ILD include&#x000a0;NSIP&#x000a0;and less commonly usual interstitial pneumonia. Of patients with collagen vascular disease, those with&#x000a0;systemic sclerosis&#x000a0;suffer the highest mortality, mainly secondary to pulmonary arterial hypertension (10%&#x000a0;to 16% prevalence).<xref ref-type="bibr" rid="article-19709.r13">[13]</xref>&#x000a0;</p>
        <p>Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disease that predominantly affects women (&#x0003e;90% of cases) and non-Whites.&#x000a0;Interstitial lung disease&#x000a0;is a rare yet insidious complication, affecting 1 in 1000 individuals, with the most common manifestation being&#x000a0;nonspecific interstitial pneumonia.<xref ref-type="bibr" rid="article-19709.r14">[14]</xref></p>
        <p>Polymyositis (PM) and dermatomyositis (DM) are inflammatory myopathies that occur most commonly in women between the ages of 40 and 50 years. The frequency of ILD is purported to be between 5% and 30%, presenting most widely as&#x000a0;nonspecific interstitial pneumonia&#x000a0;or cryptogenic organizing pneumonia, which may precede the development of clinical myositis.<xref ref-type="bibr" rid="article-19709.r14">[14]</xref>&#x000a0;</p>
        <p>As the name suggests, mixed connective tissue disease (MCTD) manifests as a combination of the above etiologies. Ninety percent of patients are female, with the incidence highest in the second and third decades.&#x000a0;Interstitial lung disease&#x000a0;is the most common pulmonary manifestation, occurring in up to 66% of patients.<xref ref-type="bibr" rid="article-19709.r15">[15]</xref><xref ref-type="bibr" rid="article-19709.r16">[16]</xref>&#x000a0;The most common pattern of&#x000a0;interstitial lung disease is nonspecific interstitial pneumonia, followed by&#x000a0;usual interstitial pneumonia and lymphocytic interstitial pneumonia, with ground glass opacities as the most frequent parenchymal abnormality.<xref ref-type="bibr" rid="article-19709.r10">[10]</xref><xref ref-type="bibr" rid="article-19709.r17">[17]</xref></p>
        <p>Sjogren's syndrome (SS) is an autoimmune disease characterized by T-cell infiltration of various organs, most often the lacrimal and salivary glands. It affects up to 3%&#x000a0;of adults, mostly women aged 30 to 40. Interstitial lung disease is more common in primary&#x000a0;Sjogren's syndrome, manifesting as&#x000a0;lymphocytic interstitial pneumonia,&#x000a0;nonspecific interstitial pneumonia,&#x000a0;usual interstitial pneumonia, or&#x000a0;cryptogenic organizing pneumonia.<xref ref-type="bibr" rid="article-19709.r18">[18]</xref><xref ref-type="bibr" rid="article-19709.r19">[19]</xref></p>
      </sec>
      <sec id="article-19709.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Interstitial lung disease&#x000a0;is characterized by a combination of chronic inflammation and a pro-inflammatory&#x000a0;cascade with varying degrees of fibrosis.<xref ref-type="bibr" rid="article-19709.r20">[20]</xref></p>
      </sec>
      <sec id="article-19709.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>On histopathologic examination,&#x000a0;interstitial lung disease associated with collagen vascular disease includes usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), diffuse alveolar damage (DAD), lymphocytic interstitial pneumonia (LIP), and apical fibrosis.<xref ref-type="bibr" rid="article-19709.r21">[21]</xref>&#x000a0;Although nonspecific, suggestive findings include lymphoid hyperplasia and prominent plasma cell inflammation&#x000a0;with interstitial inflammation.<xref ref-type="bibr" rid="article-19709.r22">[22]</xref>&#x000a0;There are varying degrees of inflammation and fibrosis, which often correspond to reticular or ground glass opacification on CT.<xref ref-type="bibr" rid="article-19709.r23">[23]</xref></p>
        <p>Usual interstitial pneumonia appears as architectural distortion, fibrosis with honeycombing, and fibroblastic foci. There are heterogeneous areas of fibrosis interspersed with normal lung parenchyma.<xref ref-type="bibr" rid="article-19709.r24">[24]</xref></p>
        <p>Nonspecific interstitial pneumonia can be classified as the cellular or fibrotic type, depending on the degree of interstitial inflammation and fibrosis. There is diffuse cellular inflammation in a homogenous pattern with patchy intervening lung tissue and preservation of lung architecture.<xref ref-type="bibr" rid="article-19709.r24">[24]</xref>&#x000a0;Fibrosing NSIP is one o the most commonly found histopathologies in ILD related to connective vascular disease.<xref ref-type="bibr" rid="article-19709.r14">[14]</xref>&#x000a0;</p>
        <p>Cryptogenic organizing pneumonia appears as intraluminal organizing fibrosis in the distal airspaces with patchy preservation of lung architecture and mild chronic interstitial inflammation.</p>
        <p>Diffuse alveolar damage appears as alveolar edema, hyaline membranes, and fibroblastic proliferation with little mature collagen.</p>
        <p>Lymphocytic interstitial pneumonia appears as infiltration of T-lymphocytes, plasma cells, and macrophages with lymphoid hyperplasia.</p>
        <p>Acute lupus pneumonitis may appear as alveolar damage and necrosis, leading to inflammatory cell infiltration, edema, and hyaline membrane formation. Histopathologic findings are commonly those of&#x000a0;usual interstitial pneumonia or nonspecific interstitial pneumonia.<xref ref-type="bibr" rid="article-19709.r25">[25]</xref></p>
        <p>In rheumatoid arthritis, interstitial pneumonitis and fibrosis are the most common manifestations.<xref ref-type="bibr" rid="article-19709.r26">[26]</xref>&#x000a0;Most patients with interstitial fibrosis have usual interstitial pneumonia or nonspecific interstitial pneumonia. Follicular bronchiolitis may be present with or without&#x000a0;fibrosing NSIP. The spectrum of histologic patterns includes pulmonary rheumatoid nodules, usual interstitial pneumonia,&#x000a0;cryptogenic organizing pneumonia, lymphoid hyperplasia, and cellular interstitial infiltrates in an NSIP-type pattern.<xref ref-type="bibr" rid="article-19709.r27">[27]</xref>&#x000a0;</p>
        <p>Systemic sclerosis frequently involves pulmonary fibrosis in both limited and diffuse forms of the disease, secondary to&#x000a0;nonspecific interstitial pneumonia or usual interstitial pneumonia, and follicular bronchiolitis or&#x000a0;cryptogenic organizing pneumonia is occasionally seen.<xref ref-type="bibr" rid="article-19709.r28">[28]</xref></p>
        <p>Although diffuse interstitial pneumonitis is uncommon in systemic lupus erythematosus, histopathologic findings are those of&#x000a0;nonspecific interstitial pneumonia&#x000a0;or usual interstitial pneumonia.<xref ref-type="bibr" rid="article-19709.r21">[21]</xref></p>
        <p>Interstitial lung disease associated with&#x000a0;polymyositis or&#x000a0;dermatomyositis&#x000a0;may manifest as cryptogenic organizing pneumonia, usual interstitial pneumonia, nonspecific interstitial pneumonia, or diffuse alveolar damage, each of which determines a different prognosis.&#x000a0;Diffuse alveolar&#x000a0;damage and&#x000a0;usual interstitial pneumonia portend a worse prognosis (30% survival at five years), contrary to those with cryptogenic organizing pneumonia&#x000a0;or&#x000a0;nonspecific interstitial pneumonia.<xref ref-type="bibr" rid="article-19709.r29">[29]</xref></p>
        <p>Mixed connective tissue disease may demonstrate interstitial fibrosis secondary to&#x000a0;usual interstitial pneumonia or&#x000a0;nonspecific interstitial pneumonia.<xref ref-type="bibr" rid="article-19709.r21">[21]</xref></p>
        <p>Sjogren&#x02019;s syndrome most commonly presents with lymphocytic interstitial pneumonia, characterized by diffuse interstitial infiltration of lymphoplasma cells, often with mild fibrosis.<xref ref-type="bibr" rid="article-19709.r30">[30]</xref>&#x000a0;Overinflation of the secondary pulmonary lobule may represent cyst formation and/or air-trapping.<xref ref-type="bibr" rid="article-19709.r31">[31]</xref></p>
      </sec>
      <sec id="article-19709.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with interstitial lung disease typically present with exertional dyspnea and nonproductive cough. Extrapulmonary symptoms such as arthralgia, myalgia, fatigue, or malaise may also be present and suggest an underlying collagen vascular disease. Past medical history of asthma&#x000a0;may suggest eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss). Family history may suggest a particular diagnosis, as some&#x000a0;collagen vascular diseases have a genetic basis. A detailed medication history is needed to exclude the possibility of drug-induced lung disease.&#x000a0;Smoking, drug use, employment history, and occupational exposure are important to ascertain, as smoking cigarettes&#x000a0;has been&#x000a0;strongly linked&#x000a0;to developing pulmonary fibrosis.<xref ref-type="bibr" rid="article-19709.r32">[32]</xref>&#x000a0;</p>
        <p>In addition, certain demographics are important distinguishers as most patients with connective&#x000a0;vascular disease-associated ILD are in the young age category (between 20 to 40 years of age). On the contrary, most patients with idiopathic pulmonary fibrosis present later (more than 60 years of age).&#x000a0;</p>
        <p>Pulmonary auscultation may reveal rales or crackles. Skin findings may include skin thickening and telangiectasias (systemic sclerosis), Raynaud phenomenon (systemic sclerosis and systemic lupus erythematosus), discoid, or butterfly rash (systemic lupus erythematosus), heliotrope rash (polymyositis and dermatomyositis), and Gottron papules (polymyositis and dermatomyositis). Xerostomia, xerophthalmia, and parotid swelling may be seen in patients with Sjogren's syndrome.<xref ref-type="bibr" rid="article-19709.r33">[33]</xref></p>
      </sec>
      <sec id="article-19709.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of interstitial lung disease can be made with pulmonary function testing (PFT) demonstrating restrictive lung disease with diminished total lung capacity (TLC), decreased forced vital capacity (FVC), and impaired diffusion of oxygen and carbon dioxide. Reduction in forced vital capacity determines the severity of restrictive physiology. PFT is predominantly a guide of disease severity and response to treatment and should not be used alone to diagnose&#x000a0;interstitial lung disease as it is nonspecific.<xref ref-type="bibr" rid="article-19709.r24">[24]</xref>&#x000a0;</p>
        <p>Autoimmune serologic testing may detect antibodies and other markers specific to certain subtypes of collagen vascular disease. Surgical lung biopsy remains the gold standard for determining the subtype of interstitial lung disease.<xref ref-type="bibr" rid="article-19709.r7">[7]</xref></p>
        <p>A chest radiograph is often the first radiologic modality used in the investigation of interstitial lung disease, though it is insufficient in making a diagnosis. The X-ray may detect basilar reticulonodular infiltrates or cystic changes in various subtypes of interstitial lung disease, though many patients with&#x000a0;interstitial lung disease may have an unremarkable study.</p>
        <p>High-resolution computed tomography (HRCT) of the chest shows various patterns in different interstitial lung diseases.</p>
        <p>In nonspecific interstitial pneumonia, there are bilateral and generally symmetric ground-glass opacities and subpleural reticulation, occasionally with microcystic honeycombing, with subpleural sparing. Traction bronchiectasis or bronchiectasis is a nearly universal feature in fibrotic nonspecific interstitial pneumonia, as is lower-lobe architectural distortion. Cellular and fibrotic&#x000a0;nonspecific interstitial pneumonia&#x000a0;are ultimately distinguished only by histology.<xref ref-type="bibr" rid="article-19709.r21">[21]</xref></p>
        <p>Usual interstitial pneumonia may be indistinguishable from nonspecific interstitial pneumonia, with ground glass opacities and subpleural reticulation in an apicobasal gradient. Consolidation and honeycombing, however, are more common in usual interstitial pneumonia.<xref ref-type="bibr" rid="article-19709.r10">[10]</xref>&#x000a0;Findings in&#x000a0;usual interstitial pneumonia include intralobular septal thickening, honeycombing, traction bronchiectasis, and subpleural reticular opacities in a peripheral, subpleural, or basal distribution. The presence of macrocytic honeycombing is typical for UIP.</p>
        <p>Lymphocytic interstitial pneumonia&#x000a0;is characterized by diffuse ground-glass opacities with thin-walled central or perivascular cysts. There may be centrilobular nodules, bronchovascular bundle thickening, and interlobular septal thickening.</p>
        <p>Organizing pneumonia appears as patchy bilateral and peripheral consolidations and ground-glass opacities. Alveolar opacities may appear triangular, polygonal, or wedge-shaped in appearance, range in size from small nodules to mass-like consolidations, and expand or migrate over time. The atoll or reverse halo sign may be appreciated.<xref ref-type="bibr" rid="article-19709.r34">[34]</xref>&#x000a0;</p>
        <p>Diffuse alveolar damage&#x000a0;demonstrates diffuse consolidation and ground-glass opacification, often with lobular sparing as well as traction bronchiectasis in later stages.<xref ref-type="bibr" rid="article-19709.r21">[21]</xref>&#x000a0;Crazy paving (a linear pattern superimposed on a background of ground-glass opacity) may be appreciated.</p>
        <p>Acute or chronic aspiration, such as from esophageal dysmotility in&#x000a0;systemic sclerosis or respiratory muscle weakness in polymyositis/dermatomyositis, may appear as centrilobular nodules, tree-in-bud opacities, and/or bronchial wall thickening.<xref ref-type="bibr" rid="article-19709.r35">[35]</xref></p>
        <p>In rheumatoid arthritis, irregular hyperattenuating areas represent intralobular lines and interlobular septal thickening. Honeycombing may be seen at the lung bases. CT patterns include subpleural reticulation or ground-glass opacities with or without honeycombing (nonspecific interstitial pneumonia, usual interstitial pneumonia,&#x000a0;cryptogenic organizing pneumonia), centrilobular branching structures with or without bronchial dilatation or traction bronchiectasis (usual interstitial pneumonia, cryptogenic organizing pneumonia), and consolidation (cryptogenic organizing pneumonia). The reticular pattern predominates in early disease, whereas honeycombing and consolidation typically appear in progressive disease.<xref ref-type="bibr" rid="article-19709.r10">[10]</xref><xref ref-type="bibr" rid="article-19709.r36">[36]</xref></p>
        <p>There may be evidence of interstitial pneumonitis and fibrosis involving the lower lobes in a peripheral and posterior distribution in systemic sclerosis.<xref ref-type="bibr" rid="article-19709.r37">[37]</xref>&#x000a0;Findings on CT have been shown to correlate with pulmonary function tests, and the extent of honeycombing significantly correlates with a decrease in diffusing capacity for carbon monoxide.<xref ref-type="bibr" rid="article-19709.r17">[17]</xref></p>
        <p>In systemic lupus erythematosus, ground-glass opacities and consolidations may reflect interstitial pneumonitis and fibrosis. Interstitial abnormalities, including interlobular septal thickening, irregular linear hyperattenuating areas, and architectural distortion, may be seen in up to one-third of patients and are commonly mild and focal.<xref ref-type="bibr" rid="article-19709.r38">[38]</xref></p>
        <p>In polymyositis and dermatomyositis, there may be prominent interlobular septa, ground-glass opacities, patchy consolidation, parenchymal bands, bronchial thickening, and subpleural lines. Consolidation with or without ground-glass opacification corresponds to cryptogenic&#x000a0;organizing pneumonia or diffuse alveolar damage. Patchy consolidations, parenchymal bands, and bronchial thickening are reversible, while&#x000a0;ground-glass opacities&#x000a0;with subpleural lines representing&#x000a0;usual interstitial pneumonia&#x000a0;may progress to honeycombing.<xref ref-type="bibr" rid="article-19709.r39">[39]</xref></p>
        <p>In mixed connective tissue disease, abnormalities may include irregular linear hyperattenuating areas with reticulation at the lung bases. In the later stages of the disease, there may be honeycombing with fibrosis extending apically, as well as areas of consolidation that may be related to cryptogenic organizing pneumonia.<xref ref-type="bibr" rid="article-19709.r21">[21]</xref></p>
        <p>In Sjogren's syndrome (SS), the most common findings on CT are bronchiectasis and centrilobular nodular or branching linear hyperattenuating areas and ground-glass opacities. The usual interstitial pneumonia (UIP) pattern is uncommon in patients with SS; the characteristic pattern of&#x000a0;lymphocytic interstitial pneumonia with extensive ground-glass opacification and thin-walled cysts may be seen. Poorly defined centrilobular nodules and bronchovascular thickening represent lymphoplasma cell infiltration of interstitial tissue.<xref ref-type="bibr" rid="article-19709.r31">[31]</xref></p>
      </sec>
      <sec id="article-19709.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of&#x000a0;collagen vascular disease-associated interstitial lung disease is geared towards the underlying connective tissue disease using pharmacological and non-pharmacological therapies.<xref ref-type="bibr" rid="article-19709.r40">[40]</xref>&#x000a0;Non-pharmacological strategies include oxygen supplementation for eligible patients, pulmonary rehabilitation, exercise, and physical therapy. Given that the clinical response to treatment varies&#x000a0;based on the underlying ILD etiology, therapeutic strategy varies too, particularly since the response&#x000a0;of connective vascular disease related-ILD tends to be more favorable&#x000a0;than&#x000a0;other types of ILD such as IPF, choice of therapy should be considered with caution.<xref ref-type="bibr" rid="article-19709.r5">[5]</xref></p>
        <p>
<bold>Immunosuppression</bold>
</p>
        <p>Immunosuppression is the&#x000a0;primary treatment of connective vascular disease-related-ILD. Although clinical trials are lacking traditionally, immunosuppression includes corticosteroids alone.&#x000a0;Prior to initiating immunosuppressive therapy, screening for infection and organ dysfunction is recommended due to the increased risk of new or reactivated infections (such as tuberculosis (TB) and hepatitis B).<xref ref-type="bibr" rid="article-19709.r41">[41]</xref><xref ref-type="bibr" rid="article-19709.r42">[42]</xref></p>
        <p>In symptomatic&#x000a0;cases of lung diseases associated with Sj&#x000f6;gren syndrome (SS) who have worsening symptoms, the most common treatment is Prednisone (starting dose&#x000a0;is 0.5 to 1 mg/kg ideal body weight&#x000a0;with&#x000a0;a maximum daily dose of 60 mg). When corticosteroid is not tolerated or lacks clinical response, immunomodulatory treatment is indicated, such as with mycophenolate or azathioprine. This&#x000a0;type of therapy is more appropriate for&#x000a0;cellular forms of ILD ( such as cellular NSIP, organizing pneumonia, or lymphoid interstitial pneumonia). There are recommendations to initiate therapy with a less toxic agent, such as azathioprine (AZA) or mycophenolate mofetil (MMF), in combination with slow tapering of&#x000a0;corticosteroid dose.<xref ref-type="bibr" rid="article-19709.r40">[40]</xref></p>
        <p>In symptomatic patients with rheumatoid arthritis-ILD and no evidence of lung infection, it is recommended t initiate treatment with&#x000a0;Prednisone with starting dose&#x000a0;is 0.5 to 1 mg/kg based on ideal body weight. (but the maximum dose should not exceed 60 mg/day).<xref ref-type="bibr" rid="article-19709.r43">[43]</xref>&#x000a0;A response usually&#x000a0;takes up to one to three months. The dose should slowly be tapered to 10 mg/day after the clinical response is achieved (based on symptoms and PFTs).&#x000a0;When there is a UIP or fibrotic NSIP pattern on HRCT or biopsy, the response to glucocorticoids is rare.</p>
        <p>In symptomatic cases of ILD associated with polymyositis and dermatomyositis, the main therapy is&#x000a0;corticosteroid alone or with a second agent to reduce inflammation and minimize progression. Usually, the estimated response rate to&#x000a0;corticosteroid alone is 50%, special when there is an NSIP pattern on HRCT. The recommended dose of therapy is similar to other connective vascular diseases associated with ILD (Prednisone with starting dose&#x000a0;is 0.5 to 1 mg/kg, ideal body weight not to exceed 50 mg /day, and to be tapered slowly after the first month of treatment).</p>
        <p>For steroid-sparing treatment or in cases of mild to moderate ILD (FVC&#x0003e;70%), azathioprine or mycophenolate can be used as a second steroid-sparing agent; however, in severe ILD (FVC &#x0003c;70% and lung involvement on HRCT &#x0003e;20%) a stronger immunosuppressive agent (such as cyclophosphamide, rituximab, or tacrolimus) should be used then&#x000a0;mycophenolate is added after the clinical response is achieved.<xref ref-type="bibr" rid="article-19709.r44">[44]</xref></p>
        <p>In rapidly progressive ILD cases&#x000a0;associated with systemic lupus erythematosus (SLE), immunosuppression with pulse intravenous (IV) methylprednisolone, IV cyclophosphamide, or rituximab&#x000a0;is usually required to control inflammation and minimize permanent lung damage.<xref ref-type="bibr" rid="article-19709.r45">[45]</xref></p>
        <p>
<bold>Antifibrotics</bold>
</p>
        <p>Treatment with antifibrosis medications (such as nintedanib and pirfenidone) has been employed recently with variable efficacy in cases where there is evidence of progressive fibrotic NSIP or UIP features (affecting more than 10% of lung volume on HRCT and forced vital capacity (FVC) of at least 45% of the predicted).<xref ref-type="bibr" rid="article-19709.r46">[46]</xref>&#x000a0;</p>
        <p>In cases of SSc-ILD and progressive fibrosing-ILD, using nintedanib led to a lower&#x000a0;annual rate of decline in FVC with similar adverse effects compared with a placebo.<xref ref-type="bibr" rid="article-19709.r47">[47]</xref>&#x000a0;Likewise,&#x000a0;pirfenidone has shown some benefit in progressive and unclassified ILD cases, including those with IPAF and acceptable safety profiles.<xref ref-type="bibr" rid="article-19709.r48">[48]</xref>&#x000a0;</p>
        <p><bold>Oxygen therapy</bold> improves breathing, facilitates exercise, prevents complications of hypoxia and pulmonary arterial hypertension, and fosters well-being. Physical rehabilitation may help improve mobility and achieve activities of daily living. Lung transplantation may be an option for patients with advanced and irreversible diseases.<xref ref-type="bibr" rid="article-19709.r20">[20]</xref></p>
        <p><bold>Lung transplantation</bold> is considered in the end-stages of cases of ILD, with similar survival rates to IPF.<xref ref-type="bibr" rid="article-19709.r49">[49]</xref>&#x000a0;The survival rates&#x000a0;in the first year&#x000a0;following lung transplant for the rheumatoid arthritis-ILD, IPF, and Scleroderma-associated ILD groups were reported to be 67%, 69%, and 82%, respectively.</p>
      </sec>
      <sec id="article-19709.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other entities that cause interstitial lung diseases, such as sarcoidosis and occupational disorders, must be considered. Acute viral pneumonia, including COVID-19 pneumonia, may also appear clinically and radiologically similar to acute exacerbation of interstitial lung disease. Cardiogenic and non-cardiogenic pulmonary edema may cause diffuse alveolar and interstitial opacities with interlobular septal thickening that may simulate interstitial lung disease.<xref ref-type="bibr" rid="article-19709.r50">[50]</xref></p>
      </sec>
      <sec id="article-19709.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Collagen vascular disease-associated interstitial lung disease is associated with significant morbidity and mortality. Collagen vascular disease-associated interstitial lung disease typically bears a better prognosis than idiopathic&#x000a0;interstitial lung disease and a slower progression than idiopathic pulmonary fibrosis. The mortality rates are similar among various connective vascular disease-related-ILD&#x000a0;(including rheumatoid arthritis, scleroderma, polymyositis, and dermatomyositis-related ILD) and remained steady over the last two decades.<xref ref-type="bibr" rid="article-19709.r51">[51]</xref></p>
        <p>Mortality is highest in women, non-Hispanic white populations, and those who develop pulmonary hypertension, have higher oxygen requirements, and require mechanical ventilation.<xref ref-type="bibr" rid="article-19709.r32">[32]</xref><xref ref-type="bibr" rid="article-19709.r52">[52]</xref>&#x000a0;Nearly 20% of patients with&#x000a0;nonspecific interstitial pneumonia&#x000a0;die within five years of diagnosis.<xref ref-type="bibr" rid="article-19709.r53">[53]</xref>&#x000a0;</p>
        <p>More extensive disease, as determined by a higher lung burden on&#x000a0;high-resolution CT and diminished forced vital capacity on&#x000a0;pulmonary function testing, correlates with future mortality in many patients.<xref ref-type="bibr" rid="article-19709.r7">[7]</xref></p>
      </sec>
      <sec id="article-19709.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Interstitial lung disease and pulmonary arterial hypertension are the main causes of mortality and morbidity in patients with collagen vascular disease.<xref ref-type="bibr" rid="article-19709.r10">[10]</xref>&#x000a0;Drug toxicity and infection are also common complications affecting this patient population.</p>
        <p>Drugs used to treat rheumatoid arthritis, such as gold salts and penicillamine, may cause diffuse alveolar damage or obliterative bronchiolitis.<xref ref-type="bibr" rid="article-19709.r9">[9]</xref>&#x000a0;Methotrexate therapy has been associated with pneumonitis.<xref ref-type="bibr" rid="article-19709.r54">[54]</xref></p>
      </sec>
      <sec id="article-19709.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>An interprofessional team involving rheumatologists and pulmonologists is often necessary to treat patients with collagen vascular disease-associated interstitial lung disease. A consensus approach by a team with expertise in&#x000a0;interstitial lung disease is considered the gold standard.<xref ref-type="bibr" rid="article-19709.r2">[2]</xref></p>
      </sec>
      <sec id="article-19709.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with a personal or family history of collagen vascular disease who present with salient physical exam findings or symptomatology should consult with a rheumatologist and/or pulmonologist to be evaluated for collagen vascular disease-associated interstitial lung disease, which may include a physical exam, pulmonary function testing, and radiologic imaging.</p>
      </sec>
      <sec id="article-19709.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diagnosing collagen vascular disease-associated interstitial lung disease and its distinction from infectious disease, hypersensitivity or drug-associated pneumonitis, and malignancy is often difficult. It requires collaboration among an interprofessional team of healthcare professionals, including clinicians, specialists, nurses, and pharmacists. Treatment and management are improved using an interprofessional approach with clinical, radiological, and pathological models for decision-making.&#x000a0;</p>
        <p>Pulmonologists must coordinate with other clinicians using open communication. Nurses and pharmacists must be empowered to inform clinicians of issues of concern they see while contributing to the case. This is in addition to their regular duties concerning patient care, medication administration, counseling, and clinical assessment. Care for collagen vascular disease-associated interstitial lung patients requires an interprofessional team effort with no communication barriers or hierarchy.</p>
        <p>A comprehensive management approach also considers comorbid conditions such as gastroesophageal reflux disease, obstructive sleep apnea, and pulmonary hypertension, as well as adjunctive therapeutic modalities such as oxygen use, exercise, and cardiopulmonary rehabilitation.<xref ref-type="bibr" rid="article-19709.r55">[55]</xref><xref ref-type="bibr" rid="article-19709.r56">[56]</xref></p>
      </sec>
      <sec id="article-19709.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19709&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19709">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/collagen-vascular-disease-associated-with-interstitial-lung/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19709">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19709/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19709">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19709.s17">
        <title>References</title>
        <ref id="article-19709.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Oldham</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Interstitial Pneumonia with Autoimmune Features: Overview of proposed criteria and recent cohort characterization.</article-title>
            <source>Clin Pulm Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>191</fpage>
            <page-range>191-196</page-range>
            <pub-id pub-id-type="pmid">29276366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mikolasch</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Garthwaite</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Update in diagnosis and management of interstitial lung disease&#x02002;.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-153</page-range>
            <pub-id pub-id-type="pmid">28365626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jindal</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Autoimmunity and interstitial lung disease.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>438</fpage>
            <page-range>438-46</page-range>
            <pub-id pub-id-type="pmid">16093819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graney</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Interstitial Pneumonia with Autoimmune Features.</article-title>
            <source>Ann Am Thorac Soc</source>
            <year>2019</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>525</fpage>
            <page-range>525-533</page-range>
            <pub-id pub-id-type="pmid">30695649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oldham</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Adegunsoye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valenzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Montner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Noth</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vij</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Strek</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Characterisation of patients with interstitial pneumonia with autoimmune features.</article-title>
            <source>Eur Respir J</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>1767</fpage>
            <page-range>1767-75</page-range>
            <pub-id pub-id-type="pmid">27103387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koo</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Uh</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.</article-title>
            <source>Korean J Intern Med</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>600</fpage>
            <page-range>600-610</page-range>
            <pub-id pub-id-type="pmid">28704913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallace</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vummidi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2016</year>
            <month>May</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>236</fpage>
            <page-range>236-45</page-range>
            <pub-id pub-id-type="pmid">27027811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Remy-Jardin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ryerson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Danoff</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Morell</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Azuma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bice</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bouros</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Collard</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Duggal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Galvin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Johkoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kazerooni</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kitaichi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Mansour</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Pipavath</surname>
                <given-names>SNJ</given-names>
              </name>
              <name>
                <surname>Buend&#x000ed;a-Rold&#x000e1;n</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Selman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>KC</given-names>
              </name>
              <collab>American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society</collab>
            </person-group>
            <article-title>Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>198</volume>
            <issue>5</issue>
            <fpage>e44</fpage>
            <page-range>e44-e68</page-range>
            <pub-id pub-id-type="pmid">30168753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in rheumatoid arthritis: recent advances.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>346</fpage>
            <page-range>346-53</page-range>
            <pub-id pub-id-type="pmid">16926650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capobianco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grimberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Jasinowodolinski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meirelles</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Thoracic manifestations of collagen vascular diseases.</article-title>
            <source>Radiographics</source>
            <year>2012</year>
            <season>Jan-Feb</season>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-50</page-range>
            <pub-id pub-id-type="pmid">22236892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid lung disease.</article-title>
            <source>Proc Am Thorac Soc</source>
            <year>2007</year>
            <month>Aug</month>
            <day>15</day>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>443</fpage>
            <page-range>443-8</page-range>
            <pub-id pub-id-type="pmid">17684286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coral-Alvarado</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pardo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;o-Rodriguez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rojas-Villarraga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anaya</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Systemic sclerosis: a world wide global analysis.</article-title>
            <source>Clin Rheumatol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>757</fpage>
            <page-range>757-65</page-range>
            <pub-id pub-id-type="pmid">19277816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLaughlin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coghlan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>48 Suppl 3</volume>
            <fpage>iii25</fpage>
            <page-range>iii25-31</page-range>
            <pub-id pub-id-type="pmid">19487219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tansey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Ip</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nikolakoupolou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Hansell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis.</article-title>
            <source>Histopathology</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>585</fpage>
            <page-range>585-96</page-range>
            <pub-id pub-id-type="pmid">15186274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burdt</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Deutscher</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sharp</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings.</article-title>
            <source>Arthritis Rheum</source>
            <year>1999</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>899</fpage>
            <page-range>899-909</page-range>
            <pub-id pub-id-type="pmid">10323445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bodolay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Szekanecz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>D&#x000e9;v&#x000e9;nyi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Galuska</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cs&#x000ed;po</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>V&#x000e8;gh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garai</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD).</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2005</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>656</fpage>
            <page-range>656-61</page-range>
            <pub-id pub-id-type="pmid">15716315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Johkoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Ichikado</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EY</given-names>
              </name>
            </person-group>
            <article-title>Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation.</article-title>
            <source>J Comput Assist Tomogr</source>
            <year>2001</year>
            <season>Sep-Oct</season>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>757</fpage>
            <page-range>757-63</page-range>
            <pub-id pub-id-type="pmid">11584237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cain</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Noble</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Matthay</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary manifestations of Sj&#x000f6;gren's syndrome.</article-title>
            <source>Clin Chest Med</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>687</fpage>
            <page-range>687-99, viii</page-range>
            <pub-id pub-id-type="pmid">9917960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parambil</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lindell</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in primary Sj&#x000f6;gren syndrome.</article-title>
            <source>Chest</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>130</volume>
            <issue>5</issue>
            <fpage>1489</fpage>
            <page-range>1489-95</page-range>
            <pub-id pub-id-type="pmid">17099028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geerts</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wuyts</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Langhe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lenaerts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yserbyt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Connective tissue disease associated interstitial pneumonia: a challenge for both rheumatologists and pulmonologists.</article-title>
            <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
            <year>2017</year>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>326</fpage>
            <page-range>326-335</page-range>
            <pub-id pub-id-type="pmid">32476865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Johkoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings.</article-title>
            <source>Radiographics</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>22 Spec No</volume>
            <fpage>S151</fpage>
            <page-range>S151-65</page-range>
            <pub-id pub-id-type="pmid">12376608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <collab>American Thoracic Society</collab>
            <collab>European Respiratory Society</collab>
            <article-title>American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2002</year>
            <month>Jan</month>
            <day>15</day>
            <volume>165</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-304</page-range>
            <pub-id pub-id-type="pmid">11790668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Hansell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Corrin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Goldstraw</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>High resolution computed tomography as a predictor of lung histology in systemic sclerosis.</article-title>
            <source>Thorax</source>
            <year>1992</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>9</issue>
            <fpage>738</fpage>
            <page-range>738-42</page-range>
            <pub-id pub-id-type="pmid">1440471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalchiem-Dekel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Galvin</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Atamas</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>NW</given-names>
              </name>
            </person-group>
            <article-title>Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History.</article-title>
            <source>J Clin Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>24</day>
            <volume>7</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">30477216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary pathology in patients with systemic autoimmune diseases.</article-title>
            <source>Clin Chest Med</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>587</fpage>
            <page-range>587-612, vii</page-range>
            <pub-id pub-id-type="pmid">9917955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanoue</surname>
                <given-names>LT</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary manifestations of rheumatoid arthritis.</article-title>
            <source>Clin Chest Med</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>667</fpage>
            <page-range>667-85, viii</page-range>
            <pub-id pub-id-type="pmid">9917959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yousem</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Carrington</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Lung biopsy in rheumatoid arthritis.</article-title>
            <source>Am Rev Respir Dis</source>
            <year>1985</year>
            <month>May</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>770</fpage>
            <page-range>770-7</page-range>
            <pub-id pub-id-type="pmid">3873887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minai</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Dweik</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Arroliga</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Manifestations of scleroderma pulmonary disease.</article-title>
            <source>Clin Chest Med</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>713</fpage>
            <page-range>713-31, viii-ix</page-range>
            <pub-id pub-id-type="pmid">9917962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tazelaar</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Viggiano</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Pickersgill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings.</article-title>
            <source>Am Rev Respir Dis</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>141</volume>
            <issue>3</issue>
            <fpage>727</fpage>
            <page-range>727-33</page-range>
            <pub-id pub-id-type="pmid">2310101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deheinzelin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Capelozzi</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Kairalla</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Barbas Filho</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Saldiva</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>de Carvalho</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in primary Sj&#x000f6;gren's syndrome. Clinical-pathological evaluation and response to treatment.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>154</volume>
            <issue>3 Pt 1</issue>
            <fpage>794</fpage>
            <page-range>794-9</page-range>
            <pub-id pub-id-type="pmid">8810621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johkoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Pickford</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hartman</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Ichikado</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akira</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Honda</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Lymphocytic interstitial pneumonia: thin-section CT findings in 22 patients.</article-title>
            <source>Radiology</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>212</volume>
            <issue>2</issue>
            <fpage>567</fpage>
            <page-range>567-72</page-range>
            <pub-id pub-id-type="pmid">10429719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mohapatra</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Padhan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and outcome of acute exacerbation in connective tissue disease-associated interstitial lung disease: A single-center study from India.</article-title>
            <source>Int J Rheum Dis</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>1741</fpage>
            <page-range>1741-1745</page-range>
            <pub-id pub-id-type="pmid">31328423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadoya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Togo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tulafu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Namba</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Iwai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Okabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kodama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ikeo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Specific Features of Fibrotic Lung Fibroblasts Highly Sensitive to Fibrotic Processes Mediated via TGF-&#x003b2;-ERK5 Interaction.</article-title>
            <source>Cell Physiol Biochem</source>
            <year>2019</year>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>822</fpage>
            <page-range>822-837</page-range>
            <pub-id pub-id-type="pmid">30946557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polverosi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maffesanti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dalpiaz</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Organizing pneumonia: typical and atypical HRCT patterns.</article-title>
            <source>Radiol Med</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>111</volume>
            <issue>2</issue>
            <fpage>202</fpage>
            <page-range>202-12</page-range>
            <pub-id pub-id-type="pmid">16671378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Argiriadi</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mendelson</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>High resolution computed tomography in idiopathic interstitial pneumonias.</article-title>
            <source>Mt Sinai J Med</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-52</page-range>
            <pub-id pub-id-type="pmid">19170217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akira</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sakatani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Thin-section CT findings in rheumatoid arthritis-associated lung disease: CT patterns and their courses.</article-title>
            <source>J Comput Assist Tomogr</source>
            <year>1999</year>
            <season>Nov-Dec</season>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>941</fpage>
            <page-range>941-8</page-range>
            <pub-id pub-id-type="pmid">10589572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Remy-Jardin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Remy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wallaert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bataille</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hatron</surname>
                <given-names>PY</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage.</article-title>
            <source>Radiology</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>188</volume>
            <issue>2</issue>
            <fpage>499</fpage>
            <page-range>499-506</page-range>
            <pub-id pub-id-type="pmid">8327704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fenlon</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Doran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sant</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Breatnach</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>High-resolution chest CT in systemic lupus erythematosus.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>166</volume>
            <issue>2</issue>
            <fpage>301</fpage>
            <page-range>301-7</page-range>
            <pub-id pub-id-type="pmid">8553934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akira</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakatani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients.</article-title>
            <source>Radiology</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>210</volume>
            <issue>2</issue>
            <fpage>333</fpage>
            <page-range>333-8</page-range>
            <pub-id pub-id-type="pmid">10207411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chartrand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of connective tissue disease-associated interstitial lung disease.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2015</year>
            <month>May</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>279</fpage>
            <page-range>279-94</page-range>
            <pub-id pub-id-type="pmid">25836643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carmona</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Reino</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Valverde</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Montero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pascual-G&#x000f3;mez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mola</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Carre&#x000f1;o</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>M</given-names>
              </name>
              <collab>BIOBADASER Group</collab>
            </person-group>
            <article-title>Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.</article-title>
            <source>Arthritis Rheum</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1766</fpage>
            <page-range>1766-72</page-range>
            <pub-id pub-id-type="pmid">15934089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Immunosuppressive agents and interstitial lung disease: what are the risks?</article-title>
            <source>Expert Rev Respir Med</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-6</page-range>
            <pub-id pub-id-type="pmid">24649876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradley</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Branley</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Greaves</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hansell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Hirani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lake</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Millar</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Wilsher</surname>
                <given-names>ML</given-names>
              </name>
              <collab>British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee</collab>
              <collab>Thoracic Society of Australia</collab>
              <collab>New Zealand Thoracic Society</collab>
              <collab>Irish Thoracic Society</collab>
            </person-group>
            <article-title>Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.</article-title>
            <source>Thorax</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>63 Suppl 5</volume>
            <fpage>v1</fpage>
            <page-range>v1-58</page-range>
            <pub-id pub-id-type="pmid">18757459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jee</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Sheehy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Corte</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Grainge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Troy</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Symons</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Glaspole</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Bleasel</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wrobel</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Dowman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>MJS</given-names>
              </name>
              <name>
                <surname>Wilsher</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>NSL</given-names>
              </name>
              <name>
                <surname>Moodley</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Keir</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.</article-title>
            <source>Respirology</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-51</page-range>
            <pub-id pub-id-type="pmid">33233015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathai</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Danoff</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Management of interstitial lung disease associated with connective tissue disease.</article-title>
            <source>BMJ</source>
            <year>2016</year>
            <month>Feb</month>
            <day>24</day>
            <volume>352</volume>
            <fpage>h6819</fpage>
            <pub-id pub-id-type="pmid">26912511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Devaraj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SLF</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tetzlaff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coeck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clerisme-Beaty</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Quaresma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haeufel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goeldner</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Schlenker-Herceg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <collab>INBUILD Trial Investigators</collab>
            </person-group>
            <article-title>Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>31</day>
            <volume>381</volume>
            <issue>18</issue>
            <fpage>1718</fpage>
            <page-range>1718-1727</page-range>
            <pub-id pub-id-type="pmid">31566307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Distler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Highland</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Gahlemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Azuma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mayes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clerisme-Beaty</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tetzlaff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuwana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
              <collab>SENSCIS Trial Investigators</collab>
            </person-group>
            <article-title>Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jun</month>
            <day>27</day>
            <volume>380</volume>
            <issue>26</issue>
            <fpage>2518</fpage>
            <page-range>2518-2528</page-range>
            <pub-id pub-id-type="pmid">31112379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Corte</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kreuter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Molina-Molina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Axmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kirchgaessler</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Samara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gilberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.</article-title>
            <source>Lancet Respir Med</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-157</page-range>
            <pub-id pub-id-type="pmid">31578169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazdani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Strand</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mittoo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2014</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>514</fpage>
            <page-range>514-20</page-range>
            <pub-id pub-id-type="pmid">24630861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atzeni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gerardi</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Barilaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Masala</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Benucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarzi-Puttini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-82</page-range>
            <pub-id pub-id-type="pmid">29202589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez P&#x000e9;rez</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Connective Tissue Disease-Interstitial Lung Disease-Associated Mortality Rates and Years of Potential Life Lost in the United States.</article-title>
            <source>Chest</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>160</volume>
            <issue>4</issue>
            <fpage>1368</fpage>
            <page-range>1368-1371</page-range>
            <pub-id pub-id-type="pmid">34625174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takizawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yanagawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kohyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Importance of interstitial lung disease in collagen vascular disease: analysis of outcome].</article-title>
            <source>Nihon Kyobu Shikkan Gakkai Zasshi</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>11</issue>
            <fpage>1177</fpage>
            <page-range>1177-81</page-range>
            <pub-id pub-id-type="pmid">8976070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Travis</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Hunninghake</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Galvin</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Cordier</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Franks</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hansell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hartman</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Kazerooni</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kitaichi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Nagai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Midthun</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Selman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2008</year>
            <month>Jun</month>
            <day>15</day>
            <volume>177</volume>
            <issue>12</issue>
            <fpage>1338</fpage>
            <page-range>1338-47</page-range>
            <pub-id pub-id-type="pmid">18388353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imokawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Helmers</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.</article-title>
            <source>Eur Respir J</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>373</fpage>
            <page-range>373-81</page-range>
            <pub-id pub-id-type="pmid">10706507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chartrand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Current approach to connective tissue disease-associated interstitial lung disease.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>449</fpage>
            <page-range>449-56</page-range>
            <pub-id pub-id-type="pmid">25022317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19709.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in connective tissue disorders.</article-title>
            <source>Lancet</source>
            <year>2012</year>
            <month>Aug</month>
            <day>18</day>
            <volume>380</volume>
            <issue>9842</issue>
            <fpage>689</fpage>
            <page-range>689-98</page-range>
            <pub-id pub-id-type="pmid">22901890</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
